Product Information
MK-8318 is a small molecule that binds to and modulates the activity of β-adrenergic receptors, which are involved in asthma therapy. The drug is orally administered and has shown efficacy in asthma patients with symptoms of bronchoconstriction. It also has been shown to be effective in animal models of asthma. MK-8318 acts as an allosteric agonist at the β2 receptor subtype and may have potential for use in other diseases such as diabetes mellitus, where it may decrease glucose levels by increasing insulin release from pancreatic cells.
The drug was first synthesized by Merck Research Laboratories in 2006 and has been used clinically as a research tool since then.
Chemical properties
Technical inquiry about: 3D-RGC58140 MK 8318
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
